ELECTROCHEMOTHERAPY IN THE TREATMENT OF UNRESECTABLE PANCREATIC CANCER
DOI:
https://doi.org/10.34287/MMT.1(52).2022.8Abstract
Pancreatic cancer (PC) is a malignant tumor with a poor prognosis and an extremely low 5-year survival rate. No more than 10% of patients have local cancer of the pancreas; in the rest, at the time of the initial diagnosis, it is already a systemic disease. In most patients, relapse occurs within the first 6 months after resection and adjuvant therapy. 95% of patients with prostate cancer require palliative therapy.
For 40 years, the results of treatment of metastatic prostate cancer have improved slightly. Gemcitabine monotherapy increased overall survival to 6 months; combinations of gemcitabine with nab-paclitaxel, liposomal irinotecan with 5-FU, or FOLFIRINOX triplet did not achieve 1-year survival.
To date, the survival limit of patients has been reached, and the likelihood of a radical change in the treatment paradigm over the next five years is very small.
The results of current clinical trials examining the effects of new drugs in prostate cancer can be expected in about 8-10 years, with an estimated success rate of about 3%.
A new method of local tumor ablation, which combines intravenous administration of cytostatics (for example, cisplatin or bleomycin) with exposure of tumor cells to constant currents with extremely short and intense pulses (8 nano-pulses of 100 microseconds duration), is the method of electrochemotherapy (clinical therapy).
Unlike radiofrequency, microwave or laser ablation, in which tissues are destroyed as a result of high temperatures with the formation of a zone of coagulation necrosis, the method of electroporation is not associated with thermal exposure, it is safer and can be used in various clinical situations, including in the treatment of cancer. pancreas.
Dynamic Electro-Amplified Chemotherapy (D-EECT) is a safe, simple and effective clinical method for treating large tumor masses. This method opens up a new direction and creates good prospects in the treatment of inoperable, chemoresistant and radioresistant tumors.
In some studies, the median time to progression (PFS) and overall survival (OS) from the moment of diagnosis in patients with unresectable prostate cancer was 22.8 and 30.7 months, respectively, which clearly exceeds the same indicators when using standard methods of anticancer chemotherapy.
The method of electrochemotherapy using Scandinavian ChemoTech AB equipment has already been registered in Ukraine and will soon improve the treatment of patients with complex tumors of various localizations, including those with unresectable forms of pancreatic cancer.
References
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10 (1): 10–27.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424.
Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog. 2012; 51 (1): 3–13.
Yamamoto T, Yagi S, Kinoshita H, [et al.]. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol. 2015; 21 (1): 262–268.
Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol. 2017; 17 (1): 143.
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362( 17): 1605–1617.
Burris HA, 3rd, Moore MJ, Andersen J, [et al.]. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15 (6): 2403–2413.
Di Magno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999; 10 Suppl 4: 140–2.
Katayama ES, Hue JJ, Bajor DL, [et al.]. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget. 2020; 11 (38): 3489–3501.
Rivera F, Benavides M, Gallego J, [et al.]. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Pancreatology. 2019; 19: 64–72.
Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318: 2306–2316.
Miklavčič D, Mali B, Kos B, [et al.]. Electrochemotherapy: from the drawing board into medical practice. BioMed Eng OnLine.2014;13: 29
Orlowski S, Belehradek J, Paoletti C, Mir L: Transient electropermeabilization of cells in culture – increase of the cyto-toxicity of anticancer drugs. Biochem Pharmacol 1988, 37: 4727–4733.
Mir LM, Orlowski S, Belehradek J Jr, Paoletti C: Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991, 27: 68–72.
Longo F, Perri F [et al.]. Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck? September 2020 Cancers 12 (10): 2781.
Davalos R, Mir L, Rubinsky B: Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005, 33: 223–231.
National Institute for Health and Care Excellence (NICE). Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma; [Internet] 2014.
Kee S, Gehl J, Lee E. Clinical Aspects of Electroporation. New York (NY): Springer; 2011.
Marty M, Sersa G, Garbay JR, [et al.]. Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Ejc Supplements. 2006; 4: 3–13.
Edhemovic I, Gadzijev EM, Brecelj E, Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat. 2011; 10: 475–485.
Miklavcic D, Sersa G, Brecelj E, Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput. 2012; 50: 1213–1225.
Granata V, Fusco R, Piccirillo [et al.].Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int. J. Surg. 2015; 18: 230–236.
Tarantino L, Busto G, Nasto A, [et al.]. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J. Gastroenterol. 2017; 23: 906–918.
Tafuto S, Von Arx C, De Divitiis C, [et al.]. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases. Int. J. Surg. 2015; 21: 78–82.
Mir LM, Gehl J, Sersa G. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 2006; 4: 14–25.
Edhemovic I, Brecelj E, Gasljevic G, [et al.]. Intraoperative electrochemotherapy of colorectal liver metastases. J. Surg. Oncol. 2014; 110: 320–327.
Granata V, Fuscoa R, Piccirillob M. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. International Journal of Surgery. 2015;18: 230–236.
